Aptose Biosciences to be Acquired by RTW Investments Affiliate
Ticker: APTOF · Form: 8-K · Filed: Jun 3, 2024 · CIK: 882361
Sentiment: bullish
Topics: acquisition, merger, healthcare
TL;DR
Aptose is getting bought by RTW for $100M ($0.70/share) - deal expected Q3.
AI Summary
Aptose Biosciences Inc. announced on June 3, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of RTW Investments, LP. The transaction is valued at approximately $100 million, with shareholders expected to receive $0.70 per share in cash. The acquisition is anticipated to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by RTW Investments, LP, a significant healthcare-focused investment firm, could lead to new strategic directions and funding for Aptose's pipeline, potentially impacting the development of its oncology therapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of the deal falling through or regulatory hurdles.
Key Numbers
- $100.0M — Transaction Value (Total amount to be paid for Aptose Biosciences Inc.)
- $0.70 — Price Per Share (Cash amount shareholders will receive for each share.)
Key Players & Entities
- Aptose Biosciences Inc. (company) — Company being acquired
- RTW Investments, LP (company) — Acquiring entity
- $100 million (dollar_amount) — Total transaction value
- $0.70 (dollar_amount) — Price per share
- June 3, 2024 (date) — Date of announcement
- third quarter of 2024 (date) — Expected closing period
FAQ
Who is acquiring Aptose Biosciences Inc.?
An affiliate of RTW Investments, LP is acquiring Aptose Biosciences Inc.
What is the total value of the acquisition?
The acquisition is valued at approximately $100 million.
How much will shareholders receive per share?
Shareholders are expected to receive $0.70 per share in cash.
When is the acquisition expected to close?
The acquisition is anticipated to close in the third quarter of 2024.
What is the filing date of this 8-K?
This 8-K filing was made on June 3, 2024.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-06-03 16:35:17
Filing Documents
- f8k_060324.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-003242.txt ( ) — 222KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_060324_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On June 3, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated June 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: June 3, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer